• About
• Links
• Contact
• Sitemap

Men's Health: The World Market for Current and Emerging Drug Therapies

This Kalorama Information report—Men’s Health: The World Market for Current and Emerging Drug Therapies—focuses on treatment segments in which men are affected. These segments include:

·Men’s Cancer

·Sexual Function

·Sexually Transmitted Diseases

·Urinary Conditions

·Andropause

The report covers drugs that are used for the treatment of conditions affecting men, including prostate cancer, impotence, and BPH; and areas where diseases and men’s health are a major concern including HIV, herpes, and urinary incontinence. Revenues for product segments include the amount estimated for use in men, for example in the area of BPH 100 percent of revenues are attributed to use in men and between 20 and 30 percent of the total urinary incontinence is calculated for the men’s health market.

The report includes statistical information for conditions and diseases affecting the men worldwide, with special emphasis on the U.S. market. Each segment provides an overview, descriptions of products on the market, products in research and development, market estimates and forecasts, and competitive analysis of leading providers. In addition to above-mentioned information, the report includes current issues and trends affecting the industry and identifies trends that may arise in the future.

Table of Contents

Chapter One: Executive Summary

• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two: Introduction

• History and Growth of the Men’s Health Industry
• Male Anatomy
• Male Reproductive Physiology
• Male Demographics and Statistics

Chapter Three: Men’s Cancer

• Description of Cancers Affecting Men
  • Prostate Cancer
  • Testicular Cancer
  • Prevalence and Incidence
• Description of Products
  • Hormone Therapies
  • LHRH Analogs
  • Antiandrogens
  • Intermittent Hormone Therapy
  • Adjuvant Hormone Therapy
  • Chemotherapy Agents
  • Others
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

Chapter Four: Men’s Sexual Dysfunction

• Description of Sexual Disorders Affecting Men
  • Erectile Dysfunction
  • Ejaculation Disorders
  • Prevalence and Incidence
• Description of Products
  • Phosphodiesterase Type V Inhibitors
  • Others
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

Chapter Five: Sexually Transmitted Diseases

• STDs Affecting Men
  • Chlamydia
  • Genital Herpes
  • Genital Warts
  • Gonorrhea
  • HIV/AIDS
  • Syphilis
• Prevalence and Incidence
• Description of Products
  • Antibiotics
  • Antiviral Therapies
  • Others
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

Chapter Six: Men’s Urinary Conditions

• Description of Urinary Conditions Affecting Men
  • Benign Prostate Hypertrophy (BPH)
  • Prostatitis
  • Urinary Incontinence
• Prevalence and Incidence
• Description of Products
  • Alpha Blockers
  • 5-Alpha Reductase Inhibitors
  • Anticholinergics
  • Antispasmodics
  • Others
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

Chapter Seven: Male Menopause or Andropause

• Description of Male Menopause
  • Prevalence and Incidence
• Description of Products
  • Androgens
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

Chapter Eight: Issues and Trends

• Education and Awareness of Men’s Health
• Changing Life Expectancy
• Legislative Issues
• Early Detection and Screening
• Prodrug Treatment
• New Guidelines for Testosterone Replacement Therapy
• Pharmaceutical Growth Trends
• Marketing Budget Trends
• Direct-to-Consumer Advertising in Europe

Chapter Nine: World Market Summary

• Overview
• Total market Size and Forecast
• Markets by Segments
• Competitor Analysis
• Market Analysis

Chapter Ten: Company Profiles

• TOP COMPETITOR PROFILES
  • Abbott Laboratories
  • ALZA Corporation
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Merck & Company, Inc.
  • Pfizer, Inc.
  • Roche Group
  • Takeda Chemical Industries Ltd.
  • TAP Pharmaceutical Products Inc.
  • Unimed Pharmaceuticals, Inc. (Solvay)
  • VIVUS, Inc.
  • Watson Pharmaceuticals, Inc.
  • Yamanouchi Pharmaceutical Company, Ltd.
• EMERGING AND R&D COMPANY PROFILES
  • Amgen, Inc.
  • Atrix Laboratories, Inc.
  • Auxilium Pharmaceuticals, Inc.
  • Bayer Corporation
  • Eli Lilly & Company
  • Gilead Sciences, Inc.
  • Hydro Med Sciences
  • Praecis Pharmaceuticals, Inc.
  • Timeris, Inc

Appendix A: Regulatory Authorities and Professional and Academic Organizations
Appendix B: Company Directory

 

List of Exhibits
Chapter One: Executive Summary

• Table 1-1: World Market for Men’s Health Pharmaceuticals 2001-2008
• Figure 1-1: World Market for Men’s Health Pharmaceuticals 2001-2008

Chapter Two: Introduction

• Table 2-1: World Male Population by Selected Geographical Region, 2002-2050
• Table 2-2: Life Expectancy at Birth by Selected Countries, 2000
• Table 2-3: United States Life Expectancy at Birth, 1990-2000, andProjections, 2005-2010
• Table 2-4: Estimated Male Prevalence of Selected Risk Behavior byGeographical Region, 2002
• Figure 2-1: Estimated Male Prevalence of Selected Risk Behavior byGeographical Region, 2002

Chapter Three: Men’s Cancer

• Table 3-1: Men’s Cancer: Estimated World Incidence and Prevalence
• Figure 3-1: Men’s Cancer: World Incidence
• Table 3-2: Research and Development: Men’s Cancer Therapies
• Table 3-3: World Market for Men’s Cancer Therapies 2001-2008
• Figure 3-2: World Market for Men’s Cancer Therapies 2001-2008
• Table 3-4: World Marketfor Men’s Cancer Therapies by ProductType 2001-2008
• Table 3-5: World Market for Men’s Cancer Therapies Distribution ofRevenues by Type 2001-2008
• Figure 3-3: World Market for Men’s Cancer Therapies Distribution ofRevenues by Type 2001-2008
• Table 3-6: U.S. Market for Men’s Cancer Therapies 2001-2008
• Figure 3-4: U.S. Market for Men’s Cancer Therapies 2001-2008
• Table 3-7: Non-U.S. Market for Men’s Cancer Therapies 2001-2008
• Figure 3-5: Non-U.S. Market for Men’s Cancer Therapies 2001-2008
• Table 3-8: World Market for Men’s Cancer Therapies Leading Suppliers’Revenues and Market Shares 2002 and 2008
• Figure 3-6: World Market for Men’s Cancer Therapies Leading Suppliers’Market Share 2002 and 2008

Chapter Four: Men’s Sexual Dysfunction

• Table 4-1: Estimated World and U.S. Incidence and Prevalence for Men’s Sexual Function
• Figure 4-1: Estimated World Prevalence of Men’s Sexual Function
• Table 4-2: Men’s Sexual Dysfunction Therapies in Research and Development
• Table 4-3: World Market for Men’s Sexual Dysfunction Therapies 2001-2008
• Figure 4-2: World Market for Men’s Sexual Dysfunction Therapies 2001-2008
• Table 4-4: World Market for Men’s Sexual Dysfunction Therapies byProduct Type 2001-2008
• Table 4-5: World Market for Men’s Sexual Dysfunction Therapies Distribution of Revenues by Product Type 2001-2008
• Figure 4-3: World Market for Men’s Sexual Dysfunction Therapies Distribution of Revenues by Product Type 2001-2008
• Table 4-6: U.S. Market for Men’s Sexual Dysfunction Therapies 2001-2008
• Figure 4-4: U.S. Market for Men’s Sexual Dysfunction Therapies 2001-2008
• Table 4-7: Non-U.S. Market for Men’s Sexual Function Therapies 2001-2008
• Figure 4-5: Non-U.S. Market for Men’s Sexual Function Therapies 2001-2008
• Table 4-8: World Market for Men’s Sexual Dysfunction Therapies Leading Suppliers’ Revenues and Market Shares 2002 and 2008
• Figure 4-6: World Market for Men’s Sexual Function Therapies LeadingSuppliers Market Share 2002 and 2008

Chapter Five: Sexually Transmitted Diseases

• Table 5-1: Men’s Sexually Transmitted Diseases: Estimated World Incidence and Prevalence for Men
• Figure 5-1: World Incidence of Men’s Sexually Transmitted Diseases
• Table 5-2: Research and Development for Sexually Transmitted DiseaseTherapies
• Table 5-3: World Market for Men’s Sexually Transmitted DiseaseTherapies 2001-2008
• Figure 5-2: World Market for Men’s Sexually Transmitted DiseaseTherapies 2001-2008
• Table 5-4: World Market for Men’s Sexually Transmitted Disease Therapies Revenues by Product Type 2001-2008
• Table 5-5: World Market for Men’s Men’s Sexually Transmitted DiseaseTherapies Distribution of Revenues by Type 2001-2008
• Figure 5-3: World Market for Men’s Men’s Sexually Transmitted DiseaseTherapies Distribution of Revenues by Type 2001-2008
• Table 5-6: U.S. Market for Men’s Sexually Transmitted DiseaseTherapies 2001-2008
• Figure 5-4: U.S. Market for Men’s Sexually Transmitted DiseaseTherapies 2001-2008
• Table 5-7: Non-U.S. Market for Men’s Sexually Transmitted DiseaseTherapies, 2001-2008
• Figure 5-5: Non-U.S. Market for Men’s Sexually Transmitted Disease Therapies, 2001-2008
• Table 5-8: World Market for Men’s Sexually Transmitted Disease TherapiesLeading Suppliers’ Revenues and Market Shares 2002 and 2008
• Figure 5-6: World Market for Men’s Sexually Transmitted Disease Therapies Leading Suppliers’ Market Shares 2002 and 2008

Chapter Six: Men’s Urinary Conditions

• Table 6-1: Men’s Urinary Conditions: Estimated World Incidence andPrevalence for Men
• Figure 6-1: Men’s Urinary Conditions: World Prevalence
• Table 6-2: Research and Development: Urinary Condition Therapies
• Table 6-3: World Market for Men’s Urinary Condition Therapies 2001-2008
• Figure 6-2: World Market for Men’s Urinary Condition Therapies 2001-2008
• Table 6-4: World Market for Men’s Urinary Condition Therapies byProduct Type 2001-2008
• Table 6-5: World Market for Men’s Urinary Condition Therapies Distribution of Revenues by Product Type 2001-2008
• Figure 6-3: World Market for Men’s Urinary Condition Therapies Distribution of Revenues by Product Type 2001-2008
• Table 6-6: U.S. Market for Men’s Urinary Condition Therapies 2001-2008
• Figure 6-4: U.S. Market for Men’s Urinary Condition Therapies 2001-2008
• Table 6-7: Non-U.S. Market for Men’s Urinary Condition Therapies 2001-2008
• Figure 6-5: Non-U.S. Market for Men’s Urinary Condition Therapies 2001-2008
• Table 6-8: World Market for Men’s Urinary Condition Therapies LeadingSuppliers’ Revenues and Market Shares 2002 and 2008
• Figure 6-6: World Market for Men’s Urinary Condition Therapies LeadingSuppliers Market Share 2002 and 2008

Chapter Seven: Male Menopause or Andropause

• Table 7-1: Andropause: Estimated World and U.S. Incidence and Prevalence
• Figure 7-1: Andropause: World Prevalence
• Table 7-2: Research and Development: Andropause Therapies
• Table 7-3: World Market for Andropause Therapies 2001-2008
• Figure 7-2: World Market for Andropause Therapies 2001-2008
• Table 7-4: U.S. Market for Andropause Therapies 2001-2008
• Figure 7-3: U.S. Market for Andropause Therapies 2001-2008
• Table 7-5: Non-U.S. Market for Andropause Therapies 2001-2008
• Figure 7-4: Non-U.S. Market for Andropause Therapies 2001-2008
• Table 7-6: World Market for Andropause Therapies Leading Suppliers’Revenues and Market Shares 2002 and 2008
• Figure 7-5: World Market for Andropause Therapies Leading Suppliers’Market Share 2002 and 2008

Chapter Nine: World Market Summary

• Table 9-1: World Market: Men’s Health, 2001-2008
• Figure 9-1: World Market for Men’s Health Pharmaceuticals 2001-2008
• Table 9-2: World Market for Men’s Health Pharmaceuticals by Therapeutic Area 2001-2008
• Table 9-3: World Market for Men’s Health Pharmaceuticals Distribution or Revenues by Therapeutic Area 2001-2008
• Figure 9-2: World Market for Men’s Health Pharmaceuticals Revenues and Distribution by Therapeutic Area 2001-2008
• Figure 9-3: World Market for Men’s Health Pharmaceuticals GraphicDistribution of Revenues by Therapeutic Area 2001-2008
• Table 9-4: Men’s Health: Leading Suppliers Significant Segments ofParticipation, 2002

 

Other users found this report page using the following search terms: mens health bph prostate erectile market size mens health world andropause cancer transmitted dysfunction prostate

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.